Disease Landscape and Forecast Insights

In 2021, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $130 billion in the major pharmaceutical markets under study (United…

In 2020, sales of branded biologics in ophthalmology reached over $8.50 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2020-2030 forecast period,…

In 2020, sales of branded biologics for respiratory indications reached nearly $1.50 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2020-…

In 2020, sales of insulins at the ex-manufacturer price level exceeded $11 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2020-2030 forecast…

In 2020, sales of erythropoiesis-stimulating agent (ESA) brands and biosimilars at the ex-manufacturer price level totaled almost $4.18 billion in the major pharmaceutical markets under study (…

Squamous cell carcinoma of the head and neck (SCCHN)—one of the most commonly diagnosed cancers in China—has a dynamic drug development pipeline, including targeted and biomarker-driven…

For neurologists, established molecules like leveteriacetam, lamotrigine, and carbamazepine remain the first choice of treatment for epilepsy; however, the new entrants in the market are evoloving…

Sickle cell disease (SCD) is a rare genetic blood disorder characterized by polymerization of hemoglobin in red blood cells that distorts them into a sickle shape. This sickling leads to several…

Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in non-small-cell lung cancer (NSCLC), breast cancer, and colorectal cancer. Biomarker-…

Since 2015, eight new brands have launched into the highly generic U.S. Parkinson’s disease (PD) therapy market, and six more are expected to launch soon. Chronic polypharmacy and progressive…

Clarivate Epidemiology’s coverage of NK/T-cell lymphoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key NHL patient populations covering 171 countries and more than 99% of…